CN102272145B - 亲和色谱基质 - Google Patents

亲和色谱基质 Download PDF

Info

Publication number
CN102272145B
CN102272145B CN201080004708.4A CN201080004708A CN102272145B CN 102272145 B CN102272145 B CN 102272145B CN 201080004708 A CN201080004708 A CN 201080004708A CN 102272145 B CN102272145 B CN 102272145B
Authority
CN
China
Prior art keywords
protein
immunoglobulin
ligand
mab
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080004708.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102272145A (zh
Inventor
H·J·约翰逊
A·伦格勒夫
R·帕尔姆格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytiva Bioprocess R&D AB
Original Assignee
GE Healthcare Bio Sciences AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Bio Sciences AB filed Critical GE Healthcare Bio Sciences AB
Publication of CN102272145A publication Critical patent/CN102272145A/zh
Application granted granted Critical
Publication of CN102272145B publication Critical patent/CN102272145B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
CN201080004708.4A 2009-01-12 2010-01-11 亲和色谱基质 Active CN102272145B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0900029 2009-01-12
SE0900029-0 2009-01-12
PCT/SE2010/050016 WO2010080065A1 (en) 2009-01-12 2010-01-11 Affinity chromatography matrix

Publications (2)

Publication Number Publication Date
CN102272145A CN102272145A (zh) 2011-12-07
CN102272145B true CN102272145B (zh) 2014-07-30

Family

ID=42316657

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080004708.4A Active CN102272145B (zh) 2009-01-12 2010-01-11 亲和色谱基质

Country Status (5)

Country Link
US (1) US20120149875A1 (enExample)
EP (1) EP2389386A4 (enExample)
JP (1) JP2012515160A (enExample)
CN (1) CN102272145B (enExample)
WO (1) WO2010080065A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
CN105152939A (zh) * 2008-11-10 2015-12-16 阿尔尼拉姆医药品有限公司 用于递送治疗剂的脂质和组合物
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
KR20230098713A (ko) * 2009-06-10 2023-07-04 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
CA2791918C (en) * 2010-03-05 2019-11-19 Boehringer Ingelheim International Gmbh Selective enrichment of antibodies
CN103228328A (zh) 2010-11-29 2013-07-31 通用电气健康护理生物科学股份公司 亲和色谱基质
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
EP2654914B1 (en) 2010-12-20 2018-05-30 GE Healthcare BioProcess R&D AB Affinity chromatography matrix
WO2012087230A1 (en) * 2010-12-20 2012-06-28 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
SG10201604554WA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
US20140221613A1 (en) * 2011-08-04 2014-08-07 Daicel Corporation Novel modified protein comprising tandem-type multimer of mutant extracellular domain of protein g
EP2831096B1 (en) * 2012-03-28 2020-04-29 GE Healthcare BioProcess R&D AB Affinity chromatography matrix
US8921113B2 (en) 2012-12-21 2014-12-30 Dionex Corporation Buffer kit and method of generating a linear pH gradient
US9896486B2 (en) * 2013-07-10 2018-02-20 Ge Healthcare Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US20160215026A1 (en) 2013-09-06 2016-07-28 Kaneka Corporation Dissociation capacity-boosted ligand for affinity dissociation matrix
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
JP7320943B2 (ja) 2016-04-28 2023-08-04 中外製薬株式会社 抗体含有製剤
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN106543274B (zh) * 2016-10-18 2020-10-27 天津大学 一种对抗体具有特异性结合作用的a蛋白结构域z的衍生物及其应用
GB201703116D0 (en) * 2017-02-27 2017-04-12 Ge Healthcare Bioprocess R&D Ab A seperation matrix and a method of seperating antibodies
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
JP7335881B2 (ja) * 2018-08-24 2023-08-30 Jsr株式会社 イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体
CN109182364A (zh) * 2018-08-30 2019-01-11 武汉百意欣生物技术有限公司 一种特异性识别蛋白a的多克隆抗体及其制备方法和应用
US11022585B2 (en) 2019-06-09 2021-06-01 Dionex Corporation Methods and systems for optimizing buffer conditions with liquid chromatography
EP4541444A1 (en) * 2023-10-20 2025-04-23 Cytiva BioProcess R&D AB Fusion protein for affinity capture

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194955A1 (en) * 2002-03-25 2006-08-31 Sophia Hober Protein ligands
US20060194950A1 (en) * 2002-03-25 2006-08-31 Sophia Hober Mutant protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1714982T3 (da) * 2001-06-05 2009-05-04 Genetics Inst Llc Fremgangsmåde til rensning af stærkt anioniske proteiner
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
SG162687A1 (en) * 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194955A1 (en) * 2002-03-25 2006-08-31 Sophia Hober Protein ligands
US20060194950A1 (en) * 2002-03-25 2006-08-31 Sophia Hober Mutant protein

Also Published As

Publication number Publication date
JP2012515160A (ja) 2012-07-05
CN102272145A (zh) 2011-12-07
EP2389386A1 (en) 2011-11-30
EP2389386A4 (en) 2013-11-06
WO2010080065A1 (en) 2010-07-15
US20120149875A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
CN102272145B (zh) 亲和色谱基质
CN103269762B (zh) 亲和色谱基质
CN103269761B (zh) 亲和色谱基质
JP4776615B2 (ja) 抗体精製
US8859726B2 (en) Affinity chromatography matrix
JP4391830B2 (ja) 変異免疫グロブリン結合タンパク質
US10189891B2 (en) Affinity chromatography matrix
AU2005296351B2 (en) A method of antibody purification
CN105377880B (zh) 突变的免疫球蛋白结合多肽
CN107108701A (zh) 修饰的κ轻链‑结合多肽
CN101043947B (zh) 一种纯化抗体的方法
WO2007142578A1 (en) Method of separating monomeric protein (s)
CN116615433A (zh) 分离基质

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160816

Address after: uppsala

Patentee after: GE HEALTHCARE BIO-SCIENCES AB

Address before: uppsala

Patentee before: GE Health Bio-science Co., Ltd.

CP01 Change in the name or title of a patent holder

Address after: uppsala

Patentee after: Situofan Biotechnology R & D Co., Ltd

Address before: uppsala

Patentee before: GE HEALTHCARE BIOPROCESS R&D AB

CP01 Change in the name or title of a patent holder